Page 2 - Chia Tai Tianqing Pharmaceutical Group Co Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

INVENTIVA: Inventiva reports its 2023 full-year results

INVENTIVA: Inventiva reports its 2023 full-year results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleSouth koreaUnited kingdomFrance generalUnited statesNew yorkGilbert dupontJulia cailleteauPascaline clercAude lepreuxSino biopharmDennis riedlEuropean investment bankChia tai tianqing pharmaceutical group co ltdMarket programChinese national medical products administration

INVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3

INVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesFrance generalNew yorkPascaline clercSino biopharmStefan klotterJulia cailleteauAude lepreuxHepalys pharma incProducts administrationEuropean investment bankBrunswick groupPatricial bankHealth care conferenceMarket program

Inventiva reports preliminary 2023 fiscal year financial

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at €.

France generalUnited statesNew yorkSouth koreaJulia cailleteauPascaline clercAude lepreuxSino biopharmMarket programHealth care conferenceProducts administrationCorporate affairsEuropean investment bankPatricial bankHepalys pharma incChia tai tianqing pharmaceutical group co ltd

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit.

South koreaUnited statesNew yorkFrance generalPascaline clercJulia cailleteauAude lepreuxSino biopharmChia tai tianqing pharmaceutical group co ltdExchange commissionData monitoring committeeBrunswick groupCorporate affairsProducts administrationHealth care conferenceMarket program

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaFrance generalUnited statesNew yorkPascaline clercSino biopharmJulia cailleteauAude lepreuxEuropean investment bankBrunswick groupHepalys pharma incProducts administrationHealth care conferenceMarket programPatricial bankChia tai tianqing pharmaceutical group co ltd